- Home
- KOS vs GENB Comparison
KOS vs GENB Comparison
Compare KOS & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | KOS | GENB |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | KOS | GENB |
|---|---|---|
| Price | $2.65 | $13.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $1.91 | ★ $23.20 |
| AVG Volume (30 Days) | ★ 16.4M | 1.0M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,288,352,000.00 | N/A |
| Revenue This Year | $27.11 | N/A |
| Revenue Next Year | N/A | $16.58 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.84 | $11.00 |
| 52 Week High | $3.34 | $18.18 |
Technical Indicators
Market Signals| Indicator | KOS | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 58.95 | 44.05 |
| Support Level | $2.33 | $11.73 |
| Resistance Level | $2.69 | $15.05 |
| Average True Range (ATR) | 0.18 | 0.86 |
| MACD | 0.06 | -0.27 |
| Stochastic Oscillator | 95.54 | 15.78 |
Price Performance
Historical ComparisonAbout KOS Kosmos Energy Ltd. (DE)
Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.
About GENB Generate Biomedicines Inc. Common Stock
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.